Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiprodil in GRIN-Related Neurodevelopmental Disorder
NCT07224581Phase 3Recruiting
- Sponsor
- GRIN Therapeutics, Inc.
- Start
- Jan 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of radiprodil in GRIN-related neurodevelopmental disorder, sponsored by GRIN Therapeutics, Inc.. Started Jan 2026; status: recruiting.
02
Drugs
radiprodil
03
Conditions
GRIN-related neurodevelopmental disorder
Beyond the preview
Go deeper on NCT07224581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07224581.